论文部分内容阅读
目的探讨阿托伐他汀治疗慢性阻塞性肺疾病(慢阻肺)伴肺动脉高压的临床疗效。方法选取洛阳市第七人民医院2014年3月—2015年10月收治的56例慢阻肺伴肺动脉高压患者,按随机双盲法将患者分为Ⅰ组和Ⅱ组,各28例。Ⅰ组给予常规治疗,Ⅱ组加用阿托伐他汀治疗。比较两组患者治疗前后患者最大呼气峰流速(PEF)、第1秒用力呼气末容积与用力肺活量比值(FEV1/FVC)、动脉血氧分压(Pa O2)、动脉二氧化碳分压(PCO2)、超敏C反应蛋白(hs-CRP)、IL-8以及临床疗效、不良反应发生情况。结果治疗前两组患者PEF、FEV1/FVC、Pa O2、PCO2比较,差异无统计学意义(P>0.05);治疗后Ⅱ组患者PEF、FEV1/FVC、Pa O2高于Ⅰ组,PCO2低于Ⅰ组,差异有统计学意义(P<0.05)。治疗前两组患者hs-CRP、IL-8比较,差异无统计学意义(P>0.05);治疗后Ⅱ组患者hs-CRP、IL-8低于Ⅰ组,差异有统计学意义(P<0.05)。Ⅱ组总有效率高于Ⅰ组,差异有统计学意义(P<0.05)。两组患者不良反应均比较轻微。结论阿托伐他汀治疗慢阻肺伴肺动脉高压的临床疗效显著,可有效改善患者肺功能和血气分析指标,减轻机体炎症程度。
Objective To investigate the clinical efficacy of atorvastatin in the treatment of chronic obstructive pulmonary disease (COPD) with pulmonary hypertension. Methods Fifty-six patients with chronic obstructive pulmonary disease who were admitted to the Seventh People’s Hospital of Luoyang from March 2014 to October 2015 were divided into two groups according to a randomized double-blind method, group Ⅰ and group Ⅱ, with 28 cases in each group. Group Ⅰ was given routine treatment, Group Ⅱ plus atorvastatin treatment. The peak expiratory flow (PEF), FEV1 / FVC, Pa O2, and PCO2 (PO2) were compared between the two groups before and after treatment. ), High-sensitivity C-reactive protein (hs-CRP), IL-8 and clinical efficacy, adverse reactions. Results There was no significant difference in PEF, FEV1 / FVC, Pa O2 and PCO2 between the two groups before treatment (P> 0.05). After treatment, the PEF, FEV1 / FVC and Pa O2 in group Ⅱ were higher than those in group Ⅰ Ⅰ group, the difference was statistically significant (P <0.05). There was no significant difference in hs-CRP and IL-8 levels between the two groups before treatment (P> 0.05). After treatment, the levels of hs-CRP and IL-8 in group Ⅱ were lower than those in group Ⅰ (P < 0.05). The total effective rate of group Ⅱ was higher than that of group Ⅰ, the difference was statistically significant (P <0.05). Adverse reactions were mild in both groups. Conclusion Atorvastatin treatment of COPD with pulmonary hypertension has a significant clinical effect, which can effectively improve the patient’s lung function and blood gas analysis indicators, reduce the degree of inflammation in the body.